2024 American Society of Clinical Oncology Annual Meeting

Schedule of DCTD Presentations

 

DCTD-supported research will be presented at the ASCO Annual Meeting from June 1- June 3, 2024.

The following tables include presentations containing DCTD staff speakers and co-authors.

• Oral Presentations
• Poster Sessions
• DCTD Staff Kiosk Schedule

Oral Presentations

Date/Time	Title	ID
June 2 4:30 - 6:00 PM CDT	Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701	7012

Poster Sessions

Date/Time	Title/DCTD Presenter (If Applicable)	ID
June 1 9:00 AM - 12:00 PM CDT	Correlations between first cycle toxicity and overall survival in patients with rare cancers treated with immune checkpoint inhibitors (NCI/SWOG S1609)	2655
	A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation	3076
	A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation	3077
	Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H	3110
	A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449)	TPS3182
	Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors Dr. Sarah Shin	TPS3187
June 1 1:30 PM - 4:30 PM CDT	ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma	4168
	Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404	9564
	A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits	9568
	Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS)	11526
	Safety and toxicity evaluation of the combination of selinexor with atezolizumab in patients with soft tissue sarcomas Dr. Jibran Ahmed	11557
	A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors	TPS4202
June 2 9:00 AM - 12:00 PM CDT	CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma	TPS6127
June 3 9:00 AM - 12:00 PM CDT	Molecular profiling of plasma from matched NCI-MATCH gynecological cancers	5579

Staff Kiosk Schedule — Booth #12023

Date	Time	Presenter
June 1	1:00 - 3:00 PM	Sharad Verma, Ph.D. Developmental Therapeutics Program
June 2	11:00 - 1:00 PM	Sharad Verma, Ph.D. Developmental Therapeutics Program
June 3	11:00 - 1:00 PM	Sharad Verma, Ph.D. Developmental Therapeutics Program
	3:00 - 5:00 PM	Beverly Teicher, Ph.D. Developmental Therapeutics Program